Intra-Cellular drug fails bipolar depression study; shares fall 14% [Reuters (UK)]
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: Reuters
Intra-Cellular drug fails bipolar depression study; shares fall 14% - Reuters 3 Min Read (Reuters) - Intra-Cellular Therapies Inc said on Monday its lead drug failed to meet the main goal of a late-stage study in patients with major depressive episodes associated with bipolar disorder. The company’s shares fell 14% before the opening bell. The treatment, lumateperone, which is being studied as a monotherapy for the condition, failed to show statistically significant improvement in the disease condition compared to placebo in the trial, the company said. The study, conducted only in the United States, tested two doses of the treatment against placebo in 554 patients. However, a second global study which tested the treatment in 381 patients, met the main goal of statistically greater improvement in the severity of depressive symptoms over placebo. The treatment is also being evaluated as an add-on therapy to lithium or valproate in a third trial. If the drug succeeds as a monotherapy on
Show less
Read more
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies to Participate in Three Upcoming Investor ConferencesGlobeNewswire
- Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI CongressGlobeNewswire
- Intra-Cellular bolsters Caplyta data with another Phase III win [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with SchizophreniaGlobeNewswire
ITCI
Earnings
- 10/30/24 - Miss
ITCI
Sec Filings
- 11/14/24 - Form 4
- 11/12/24 - Form 144
- 11/12/24 - Form SC
- ITCI's page on the SEC website